Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.
|NCT04625270||II||Recurrent low grade serous ovarian cancer with KRAS MUT||A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)||AZ, CA, CT, FL, IL, MN, MO, NV, NM, NY, OH, OK, OR, TN, TX, VA||View Drugs||View Results |
|VS-6766||CKI27, RO5126766, Raf/MEK dual kinase inhibitor RO5126766, CH5126766||RAF and MEK inhibitor||Clinical Trials|
|Defactinib||VS-6063, PF-04554878, PF-04554878||FAK inhibitor||Clinical Trials|